Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy

Serum Tumor Necrosis Factor Alpha (TNF-Α) Levels after Anti-Tuberculous Therapy

The monocyte/macrophage-derived cytokine, Tumor Necrosis Factor Alpha (TNF-α) plays a central role in effective granulomatous immunity to Mycobacterium tuberculosis infections in humans. The present study was conducted to document changes in the serum TNF-α level of patients after varying durations of anti-tuberculous therapy as compared to normal healthy controls. A comparative study was condu...

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Patients receiving anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy are at increased risk for tuberculosis and other granulomatous diseases, but little is known about illness caused by nontuberculous mycobacteria (NTM) in this setting. We reviewed the US Food and Drug Administration MedWatch database for reports of NTM disease in patients receiving anti-TNF-alpha therapy. Of 239 report...

Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.

3. Information on permissions/orders of reprints in rheumatology and related fields. Silverman featuring research articles on clinical subjects from scientists working is a monthly international serial edited by Earl D.

Alopecia secondary to anti-tumor necrosis factor-alpha therapy*

Biologic drugs represent a substantial progress in the treatment of chronic inflammatory immunologic diseases. However, its crescent use has revealed seldom reported or unknown adverse reactions, mainly associated with anti-tumor necrosis factor (anti-TNF). Psoriasiform cutaneous reactions and few cases of alopecia can occur in some patients while taking these drugs. Two cases of alopecia were ...

Autoimmune Pitfalls of Anti-Tumor Necrosis Factor-Alpha Therapy.